Biologic Development Image


Kirtland Poss, President & CEO

Mr. Poss is co-founder, President and CEO of BioAnalytix. Previously, Mr. Poss founded and ran the molecular imaging company VisEn Medical as President and CEO from its early technology platform formation in 2000 through product development, worldwide commercialization, pharmaceutical partnerships, and M&A with PerkinElmer in 2010. In his role with VisEn, Mr. Poss led the development, launch and commercialization of multiple molecular imaging systems and agent product lines, and also ran several of VisEn’s strategic partnerships with leading pharmaceutical companies and clinical research centers in applying VisEn’s molecular imaging agents in pharmaceutical development pipelines and clinical trials. Before VisEn, Mr. Poss worked in healthcare business strategy consulting for Kendall Strategies in Cambridge, MA, and prior to that he worked in scientific research at the Center for Molecular Imaging Research at the Massachusetts General Hospital and Harvard Medical School. He is a co-author on several scientific publications and multiple patents in the fields of biomarker imaging and pharmaceutical development.

Shiaw-Lin (Billy) Wu, PhD, Chief Scientific Officer

Dr. Wu is Chief Scientific Officer of BioAnalytix. Dr. Wu developed his expertise in advanced analytics and biologic drug development with Genentech, where he spent nine years in areas of protein chemistry and advanced analytical methods for complex characterizations of biologic pharmaceuticals. After that, he further developed his analytic expertise with ThermoFisher Scientific where he worked in developing methods and applications of hybrid mass spectrometry in proteomics. During his time at the Barnett Institute, Dr. Wu focused on various advanced analytical techniques and methods for complex protein analysis and biologic drug characterization, including ETD for complicated disulfide characterization, LC-MS for biosimilar comparison mapping, and protein PK/PD characterization analyses using unique sample preparation techniques combined with hybrid mass spectrometry. Dr. Wu’s primary focus has been in applying these advanced analytical approaches in biologic drug development and regulatory strategies with multiple pharmaceutical and biotechnology companies in the US and abroad. He has published more than 70 scientific papers in these areas.

Jennifer S. (Laurence) Chadwick, PhD, Director of Biologic Development

Dr. Chadwick is the Director of Biologic Development at BioAnalytix. Prior to joining BioAnalytix, Dr. Chadwick was a tenured Professor and Louise Byrd Graduate Educator in the Department of Pharmaceutical Chemistry at the University of Kansas. She is an expert in the analysis of proteins, and her academic research focused particularly on understanding the molecular mechanisms underlying instability of proteins and their stabilization by exogenous compounds. During her twelve years at KU, Prof. Chadwick also engaged in biologic drug development and collaborated and consulted with numerous pharma/biotech companies to investigate stability problems and related formulations in therapeutic proteins, including monoclonal antibodies and antibody drug conjugates (ADCs). Her academic work spanned a diverse set of research problems, including biomaterials, and has resulted in over 50 peer-reviewed publications, 13 patents and 4 book chapters. Dr. Chadwick is an Associate Director of CASSS and Visiting Scholar in the Department of Chemistry and Chemical Biology at Northeastern University as well as an Editorial Advisory Board member for Journal of Pharmaceutical Sciences and Scientific Reports. She received her PhD from Purdue University, Department of Chemistry for her quantitative analysis of interactions between immunoregulatory cytokines and a diverse set of partner molecules

Lily Li, PhD, Senior Director of Lab Process and Platform Development

Dr. Li is the Senior Director of Process and Platform Development of BioAnalytix. Previously, Dr. Li was Laboratory Director at Tandem Labs, New England, where she oversaw operations and built quality systems to support pharmaceutical DMPK and biomarker R&D from early discovery through clinical development. Before joining Tandem Labs, Dr. Li was the Director of Analytics, Mass Spectrometry and the Founding Scientist at Cantata Pharmaceuticals, where she launched a biomarker-based CLIA certified laboratory. As High Throughput Analytics Lead at Monsanto, she led teams and built biochemical profiling platforms which were used to support Monsanto company-wide Genomics pipeline and Biotech research projects. Dr. Li is a co-author on several patents in methods and processes of small and large molecules analysis. Dr. Li was an NIH post-doctoral fellow in Drug Testing and Toxicology and received her Ph.D. in Food Chemistry at Cornell University. She earned her M.S. in Nutritional Biochemistry at University of Illinois, Urbana-Champaign.

John Ziolkowski, Chief Financial Officer

Mr. Ziolkowski is Chief Financial Officer at BioAnalytix. He brings more than 20 years of financial and operational management experience to BioAnalytix. Most recently, he served as CFO of SiOnyx, a CMOS image sensor company. Prior to SiOnyx, John was CFO at VisEn Medical, a leading biomarker imaging company acquired by PerkinElmer in 2010. In these roles, John oversaw all aspects of finance, operations, IT, legal compliance and human resource management. Previously, Mr. Ziolkowski served as CFO at Axsun Technologies, a market-leading optoelectronic instrumentation manufacturer. Mr. Ziolkowski joined Axsun from PricewaterhouseCoopers LLP, where he advised a cross section of public and private technology companies as a manager in the Technology Practice of the Audit and Business Advisory Services Group. Mr. Ziolkowski holds a B.A. in Economics/Accounting from the College of the Holy Cross and is also a Certified Public Accountant.

Dongdong Wang, PhD, Director of Analytical Science

Dr. Wang is currently Director of Analytical Science at BioAnalytix, where he is combining his biotherapeutic development experience with mass spectrometry-based techniques to address specific needs from pharmaceutical and biotech companies. Before joining BioAnalytix, he was Group Leader of the mass spectrometry core lab in the DMPK-Bioanalysis department at AbbVie, and was responsible for the pre-clinical pharmacokinetics assessment of antibody-drug conjugates and in-vitro/in-vivo stability screening for novel biological modalities. Before DMPK, he was Senior Scientist in the process sciences department at AbbVie, where he was the key team member to advance an antibody-drug conjugate program from pre-clinical to Phase II under accelerated timelines. Dr. Wang has broad experiences in the application of advanced analytics in biologics development, including candidate selection, developability assessment, method qualification/transfer, comparability study and CQA/specification setting. Dr. Wang has ~10 publications, with the most two recent reviews focusing on comparability studies and developability assessments of mAbs. Dr. Wang earned his PhD from Northeastern University at the Barnett Institute of Chemical and Biological Analysis, where he developed sensitive LC-MS techniques to study the site-specific glycosylation changes of serum protein from cancer patients.

Mary Bowen, Director of Strategic and Digital Marketing

As the Director of Strategic and Digital Marketing, Mary Bowen drives the marketing strategy to create growth, awareness, and demand for BioAnalytix. She brings 12 years of digital marketing, web development, and branding experience to the company. Before joining BioAnalytix, Mary served as the Head of Digital Marketing and Creative at RainDance Technologies, which was acquired by Bio-Rad Laboratories. She spearheaded the company's global marketing campaigns to promote the cancer detection instruments to hospitals, academic institutions, and worldwide cancer centers. Prior to RainDance Technologies, Mary oversaw the marketing programs for an eCommerce recruiting platform and SaaS provider for career centers,, now owned by Symplicity. The audience consisted of 1.2 million college students, Fortune 500 Companies, and 3,500 prestigious Colleges and Universities nationwide. Over the past decade, Mary has also served as an advisor to young innovative startups and non-profits to help them get started with their branding, digital marketing strategies, and their web and mobile app development. Mary holds a BSBA in Entrepreneurship at Suffolk University and a User Experience Certificate at Bentley University.

Back to top